Our coverage on the latest scoop
News and Media Releases
ATMA’s First Psychedelic Training Program for Physicians and Prescribers begins April 14, 2023
As psychedelic therapy regulations are being implemented, drafted and discussed...
READ MORE
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
First-of-its-kind clinical trial establishes the Company’s drug pipeline and strategic...
READ MORE
ATMA OFFERS PSYCHEDELIC-ASSISTED THERAPY TRAINING IN AUSTRALIA TO SUPPORT PSYCHIATRISTS AND HEALTHCARE PROFESSIONALS
In response to Australia’s approval of MDMA and psilocybin use in therapy...
READ MORE
ATMA AND LINDEN MEDICAL CENTRE TO BECOME AFFILIATE PARTNERS
CALGARY, ALBERTA, CANADA, February 3, 2023 /EINPresswire.com/ — ATMA Journey Centers...
READ MOREATMA Provides Alberta Health Services (AHS) Healthcare Professionals Group Discount on Psychedelic Therapy Education
CALGARY, ALBERTA, CANADA, January 25, 2023 /EINPresswire.com/ — In response...
READ MOREATMA Offers the First Psychedelic Training Program for Physicians and Prescribers
CALGARY, ALBERTA, CANADA, January 18, 2023 /EINPresswire.com/ — ATMA Journey Centers...
READ MOREATMA and Neuma Centre Partner to Create Access to first of its kind Psilocybin Research Trial in Ontario
KINGSTON, ONTARIO, CANADA, January 5, 2023 /EINPresswire.com/ — ATMA Journey Centers...
READ MORE
ATMA and QI Integrated Health to Become Affiliate Partners
VANCOUVER, BRITISH COLUMBIA, CANADA, December 8, 2022 /EINPresswire.com/ — ATMA Journey...
READ MORE
Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date
ATMA’s N500 Phase II Clinical Trial will assess psilocybin efficacy...
READ MORE
ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants
Fourteen healthy subjects completed an experiential session after receiving 25...
READ MORE